Not Tagged
allogene therapeutics
['$allo']
bofa $allo's asco is unlikely to be stock impactful. maintain underperform, po unchanged, remain unconvinced of competitive positioning for allogene's cart offerings.
BIOTECH man LONGTERM FOCUS many positions-also trade around my CORE holdings my opinion only do your own research with me